In addition, 68Ga-Pentixafor exhibited a significantly higher uptake in patients with higher tumor grade, high proliferative index and triple-negative breast cancer (TNBC), as well as HIV-infected breast cancer patients, highlighting the potential clinical utility and prognostic role of CXCR4-targeted PET imaging in aggressive breast cancer. This evidence concerns the gene CXCR4 and triple-negative breast carcinoma.